Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Oral Dis ; 22(7): 649-57, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27232600

ABSTRACT

OBJECTIVES: Characterize the cell profile and immunostaining of proinflammatory markers in an experimental model of bisphosphonate-related osteonecrosis of the jaw (BRONJ). MATERIALS AND METHODS: Male Wistar rats (n = 6-7) were treated chronically with saline solution or zoledronic acid (ZA) at 0.04, 0.20, and 1.00 mg kg(-1) (1.4 × 10(-7) , 6.9 × 10(-6) , and 3.4 × 10(-5)  mol kg(-1) ), and subsequently, the first left inferior molar was extracted. Were performed counting of viable and empty osteocyte lacunae, viable and apoptotic osteoclasts, polymorphonuclear neutrophil, mast cells (toluidine blue), and the positive presence cells for CD68, tumor necrosis factor-alpha (TNF-α), IL (interleukin)-1ß, inducible nitric oxide synthase (iNOS), nuclear factor-kappa B (NF-kB) and IL-18 binding protein (IL-18 bp). RESULTS: BRONJ was showed in ZA treated with 0.20 and 1.00 mg kg(-1) . There is a dose dependent increase in percentage of empty osteocyte lacunae (P < 0.001) and apoptotic osteoclasts (P < 0.001), counting of total osteoclasts (P = 0.003), polymorphonuclear neutrophil cells (P = 0.009), cytoplasmic-positive cells of CD68 (P < 0.001), TNF-α (P = 0.001), IL-1ß (P = 0.001), iNOS (P < 0.001), NF-kB (P = 0.006), and nuclear-positive cells of NF-kB (P = 0.011). Consequently, there is no difference in mast cells (P = 0.957), and IL-18 bp immunostaining decreases dose dependently (P = 0.005). CONCLUSIONS: BRONJ is characterized by increases in immunostaining for proinflammatory markers and NF-kB and inversely associated with cells exhibiting IL-18 bp.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/immunology , Animals , Biomarkers/analysis , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Immunohistochemistry , Male , Models, Animal , Rats , Rats, Wistar
2.
J Laryngol Otol ; 123(6): 590-7, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19144244

ABSTRACT

BACKGROUND: Although most studies on animal ototoxicity employ scanning electron microscopy, all cochlear structures may be identified with light microscopy. This paper describes a simple method of histological assessment of cisplatin-induced ototoxicity in rats, and relates morphological changes to functional changes in hearing detected by distortion product evoked otoacoustic emissions. MATERIALS AND METHODS: Male Wistar rats were injected with 8 mg/kg/day cisplatin, or with an equivalent volume of saline solution, for three consecutive days. They underwent distortion product evoked otoacoustic emission testing at baseline and at 24 or 48 hours after the last administration. At the end of the experiment, the animals were sacrificed and their cochleae were retrieved and prepared for haematoxylin and eosin staining. RESULTS: A four-point scoring system was used to grade injury to the external ciliated cells, as indicated by the number of cells absent from the basal turn of the cochlear duct. A four-point scoring system was also used to grade stria vascularis injury, as indicated by the degree of shrinkage of the intermediate cells. Scores were significantly higher in groups treated with cisplatin compared with controls. Morphological changes were confirmed by decreased distortion product evoked otoacoustic emission amplitudes in animals treated with cisplatin. CONCLUSION: This method is simple to perform with routine histology equipment and is appropriate for the study of acute, cisplatin-induced ototoxicity in rats.


Subject(s)
Cisplatin/toxicity , Cochlea/drug effects , Hearing Loss/chemically induced , Otoacoustic Emissions, Spontaneous/drug effects , Animals , Cochlea/pathology , Hearing Loss/physiopathology , Male , Microscopy, Polarization , Rats , Rats, Wistar , Reference Values
3.
Eur J Oral Sci ; 108(2): 123-9, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10768725

ABSTRACT

Chlorpromazine (CPZ), a phenothiazine derivative, possesses anti-inflammatory properties, inhibition of tumor neurosis factor-alpha (TNF-alpha) synthesis and bone resorption. TNF-alpha promotes inflammatory changes and bone resorption in periodontitis. We have studied the effect of CPZ in experimental periodontitis. Wistar rats were subjected to a ligature placement around the cervix of the right second upper molars. Alveolar bone loss was evaluated by the sum of the distances between the cusp tip and the alveolar bone along the axis of each molar root, which was subtracted from the contralateral side. Histopathological analysis of the periodontium was based on cell influx, osteoclast number, and alveolar bone and cementum integrity. Animals were weighed daily and total and differential peripheral white blood cell counts were performed 6 h and 1, 7 and 11 d after periodontitis induction. Groups were treated with CPZ 1 h before and daily up to the 11th d of periodontitis. Alveolar bone loss was inhibited 46%, 55.4%, and 76.5% by CPZ at 1, 3 and 9 mg/kg, respectively. Histological analysis showed a significant reduction of cell influx and osteoclast number, as well as preservation of the alveolar process and cementum. CPZ reversed leukocytosis but not weight loss. In conclusion, CPZ reduces bone loss in experimental periodontitis, probably via TNF-alpha blockade.


Subject(s)
Alveolar Bone Loss/drug therapy , Anti-Inflammatory Agents/therapeutic use , Chlorpromazine/therapeutic use , Dopamine Antagonists/therapeutic use , Periodontitis/drug therapy , Alveolar Bone Loss/pathology , Alveolar Bone Loss/prevention & control , Alveolar Process/drug effects , Analysis of Variance , Animals , Bone Resorption/prevention & control , Cell Count/drug effects , Dental Cementum/drug effects , Leukocyte Count/drug effects , Leukocytosis/drug therapy , Male , Molar/pathology , Osteoclasts/drug effects , Periodontitis/pathology , Periodontitis/prevention & control , Rats , Rats, Wistar , Tooth Cervix/pathology , Tooth Root/pathology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Weight Loss
SELECTION OF CITATIONS
SEARCH DETAIL
...